Scientists identify genetic drivers of leukaemia

August 2, 2012

(Medical Xpress) -- Scientists at Newcastle University have discovered three key genetic errors which can dictate how adult patients develop leukaemia and respond to treatment and could help doctors adapt future treatments.

This breakthrough study published today in the , could help doctors form a more accurate prognosis for each patient and adjust treatment accordingly.

Acute (ALL) is a which is characterised by the uncontrollable multiplication of genetically mutated , which crowd out healthy blood cells.

The Newcastle University team, which was funded by the charity Leukaemia & Lymphoma Research, studied nine newly discovered genetic mutations in the leukaemia cells of 450 adolescents and adults diagnosed with ALL. The researchers added this new information to existing data to generate the most comprehensive genetic profile of adolescent and adult ALL compiled to date.

In the paper the Newcastle University team showed that the incidence of the new mutations was higher than expected, with over two thirds of patients found to carry at least one. Moreover three of the new mutations were shown to be ‘high risk’ markers and patients carrying one of the mutations had a greater risk of relapse or death when treated with standard therapy.

Over one quarter of patients harboured one or more of these high risk mutations, an incidence higher than that observed among children with ALL.

Professor Anthony Moorman, who led the team at the Northern Institute for Cancer Research at Newcastle University, said: “This study represents a significant advance in our understanding of the clinical relevance of genetics in adult ALL. While over 80% of children with ALL are now cured, survival rates for adults are much lower.

“Identifying the precise genetic abnormalities in each patient’s cancer has proven extremely useful in helping to guide the treatment of childhood leukaemia and understand how the disease develops. We hope that this research will contribute to helping repeat this success in adults, where better prognostic tools are desperately needed.”

Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, said: “By identifying high-risk genetic profiles in adult leukaemia patients, doctors should be able to better ensure each individual receives the right level and type of treatment for his or her disease. More research needs to be done into these three genetic mutations and how these can be ‘targeted’ by new drugs.”

Explore further: Scientists discover how common treatment-related cancer develops

More information: jco.ascopubs.org/content/early … 011.40.3907.abstract

Related Stories

Scientists discover how common treatment-related cancer develops

May 31, 2012
(Medical Xpress) -- Scientists in a team at Newcastle University have identified a mechanism by which treatment-related leukaemia develops, raising hopes that this side effect of toxic chemotherapy could be prevented.

Scientists find genetic key to why some cancer patients don't respond to treatment

January 5, 2012
(Medical Xpress) -- Researchers from Newcastle University have identified a gene variation carried by 20% of the population which can significantly affect how patients with a rare type of blood cancer will respond to treatment.

Scientists find new drug target for hard-to-treat leukaemia

March 30, 2012
(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

Cancer Research UK launches trial of new drug to treat acute childhood leukaemia

January 27, 2012
Cancer Research UK’s Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment.

Researchers’ blood cancer breakthrough

August 10, 2011
Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed.

Drug's 'double hit' overcomes leukaemia resistance

July 13, 2012
A drug that uses a unique ‘double hit’ to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, majority funded by Cancer Research UK, is published this ...

Recommended for you

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.